Item 16. Form 10-K Summary

Not applicable.

123

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Eli Lilly and Company


By						/s/ David A. Ricks
David A. Ricks
Chair, President, and Chief Executive Officer

February 23, 2022

124

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 23, 2022 by the following persons on behalf of the Registrant and in the capacities indicated.


Signature						Title

/s/ David A. Ricks						Chair, President, and Chief Executive Officer (principal executive officer)
DAVID A. RICKS

/s/ Anat Ashkenazi						Senior Vice President and Chief Financial Officer (principal financial officer)
ANAT ASHKENAZI

/s/ Donald A. Zakrowski						Vice President, Finance, and Chief Accounting Officer (principal accounting officer)
DONALD A. ZAKROWSKI

/s/ Ralph Alvarez						Director
RALPH ALVAREZ

/s/ Katherine Baicker, Ph.D.						Director
KATHERINE BAICKER, Ph.D.

/s/ Michael L. Eskew						Director
MICHAEL L. ESKEW

/s/ J. Erik Fyrwald						Director
J. ERIK FYRWALD

/s/ Jamere Jackson						Director
JAMERE JACKSON

/s/ Kimberly H. Johnson						Director
KIMBERLY H. JOHNSON

/s/ William G. Kaelin, Jr., M.D.						Director
WILLIAM G. KAELIN, JR., M.D.

/s/ Juan R. Luciano						Director
JUAN R. LUCIANO

/s/ Marschall S. Runge, M.D., Ph.D.						Director
MARSCHALL S. RUNGE, M.D., Ph.D.

/s/ Gabrielle Sulzberger						Director
GABRIELLE SULZBERGER

/s/ Jackson P. Tai						Director
JACKSON P. TAI

/s/ Karen Walker						Director
KAREN WALKER

125

Trademarks Used In This Report

Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this report, appear with an initial capital and are followed by the symbol ® or ™, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.

Actos*®* is a trademark of Takeda Pharmaceutical Company Limited.

Byetta® is a trademark of Amylin Pharmaceuticals, Inc.

Glyxambi®, Jardiance®, Jentadueto®, Synjardy®, Trajenta®, and Trijardy® are trademarks of Boehringer Ingelheim International GmbH.

Tyvyt® is a trademark of Innovent Biologics (Suzhou) Co., Ltd.

Viagra*®* is a trademark of G.D. Searle LLC, a Viatris Company.

126

Previous: Item 15. Exhibits and Financial Statement Schedules